kontakt@femireform.se 0768535782 Kungsgatan 111 Vån 2 Kungshörnet. Klövern, 75318 Uppsala
Info & studier
Information

ISSN: ISSN 1855-9913 Ursp. publicerad: Journal of the Laser and Health Academy Vol. 2013, No.1; www.laserandhealth.com

Författare

Johanna Koch
Arbetsplats: Laser Medizin Zentrum Rhein-Ruhr , Germany

Länkar
Suffix/Referenser

The intent of this Laser and Health Academy publication is to facilitate an exchange of information on the views, research results, and clinical experiences within the medical laser community. The contents of this publication are the sole responsibility of the authors and may not in any circumstances be regarded as official product information by medical equipment manufacturers. When in doubt, please check with the manufacturers about whether a specific product or application has been approved or cleared to be marketed and sold in your country.

Forskningsstudie 1: IncontiLase/IntimaLase – our Findings

IncontiLase/IntimaLase – our Findings, 2013, Koch

ABSTRACT

Stress urinary incontinence is defined as involuntary leakage of urine during physical activities that may cause impairment in social and sexual life [1]. In Germany there is still poor awareness of this problem through all medical disciplines.
With development of the IntimaLase™ (Fotona Slovenia) and IncontiLase™ (Fotona, Slovenia) treatments, novel minimally invasive laser therapies for vaginal laxity and stress urinary incontinence were introduced [2,3].
To elucidate the applicability of these novel treatments, 22 patients aged between 31 to 62 years suffering from mild or moderate stress urinary incontinence were treated from May 2012 to May 2013 in our Laser Medicine Center.
All patients underwent gynecological examinations 1 month prior to the IncontiLase treatment. All patients were in good health. For evaluation of muscle tone/contractility before and after the treatment, pelvic floor muscle pressure was measured with PFX®-manometer.
The treatment followed a Fotona protocol using the Fotona SP Spectro® Er:YAG SMOOTH mode with a 7 mm spot size PS03 handpiece, 10 J/cm2 fluence; 1.6 – 2 Hz.
No anesthesia was needed for deeper parts of the treatment area, while in the external treatment site lidocaine gel, lidocaine/tetracaine cream or lidocaine spray was used. Most patients reported mild to no pain. Patients were reporting discomfort especially in the external area, which increased with the number of laser pulses applied.
To assess the duration of effects, evaluation was conducted at 1, 2, 3 and up to 9 months after the treatment.
All patients were satisfied with the results of the treatment, with no side effects reported, and 30% of the patients considered a second treatment for further improvement.

Our experiences with 22 patients showed that the IncontiLase treatment presents an effective, minimally invasive method for treating stress urinary incontinence.